Review: Placental programming of postnatal diabetes and impaired insulin action after IUGR

Area of Science:

• Endocrinology
• Developmental Biology
• Metabolic Disease Research

Background:

• Poor fetal growth, or intrauterine growth restriction (IUGR), elevates the risk of developing type 2 diabetes later in life.
• This increased risk is linked to impaired insulin secretion and reduced insulin sensitivity.
• Placental insufficiency is a primary driver of IUGR, impacting fetal development and long-term metabolic health.

Purpose of the Study:

• To investigate the mechanisms linking impaired fetal growth to later metabolic dysfunction.
• To utilize animal models of restricted placental growth (PR) to study changes in insulin secretion and sensitivity.
• To identify and develop interventions targeting epigenetic modifications to prevent or reverse adverse metabolic outcomes.

Main Methods:

• Utilizing non-human animal models with restricted placental growth (PR) to mimic human IUGR.
• Analyzing changes in insulin secretion and sensitivity in PR models.
• Investigating epigenetic modifications, specifically at the Pdx-1 promoter, and their impact on gene expression and insulin action.

Main Results:

• Restricted placental growth in animal models recapitulates the insulin secretion and sensitivity deficits observed in human IUGR.
• Epigenetic changes at the Pdx-1 promoter in PR models are associated with reduced Pdx-1 transcription factor expression.
• These epigenetic alterations are implicated in impaired insulin secretion.

Conclusions:

• Animal models of restricted placental growth are valuable tools for understanding IUGR-related metabolic disease.
• Epigenetic modifications play a crucial role in the development of impaired insulin action following adverse fetal environments.
• Developing interventions to reverse these epigenetic changes holds promise for treating human IUGR and preventing future metabolic disease.